US 2023/0054718 A1Published application

Anti-galectin-9 antibody and uses thereof

AssigneeHifibio (Hk) Limited

InventorsGermain MARGALL DUCOS, Rachel PACHERIE, Nicola Arturo Aldo BELTRAMINELLI, Francisco ADRIAN, Liang SCHWEIZER, Muriel DAVID, Yun-Yueh LU

Life of this patent

Estimating the term…

Abstract

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1/PD-L1 immune checkpoint.

Claims32

Dependent claims

An isolated monoclonal antibody, or an antigen-binding fragment thereof, wherein, said monoclonal antibody or antigen-binding fragment thereof is specific for Galectin-9, and wherein said monoclonal antibody comprises:

(1a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
2, a HCVR CDR2 sequence of SEQ ID NO:
4, and a HCVR CDR3 sequence of SEQ ID NO:
6;
and,
(1b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
10, a LCVR CDR2 sequence of SEQ ID NO:
12, and a LCVR CDR3 sequence of SEQ ID NO:
14;
or
(2a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
18, a HCVR CDR2 sequence of SEQ ID NO:
20, and a HCVR CDR3 sequence of SEQ ID NO:
22;
and,
(2b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
26, a LCVR CDR2 sequence of SEQ ID NO:
28, and a LCVR CDR3 sequence of SEQ ID NO:
30;
or
(3a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
34, a HCVR CDR2 sequence of SEQ ID NO:
36, and a HCVR CDR3 sequence of SEQ ID NO:
38;
and,
(3b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
42, a LCVR CDR2 sequence of SEQ ID NO:
44, and a LCVR CDR3 sequence of SEQ ID NO:
46;
or
(4a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
50, a HCVR CDR2 sequence of SEQ ID NO:
52, and a HCVR CDR3 sequence of SEQ ID NO:
54;
and,
(4b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
58, a LCVR CDR2 sequence of SEQ ID NO:
60, and a LCVR CDR3 sequence of SEQ ID NO:
62;
or
(5a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
66, a HCVR CDR2 sequence of SEQ ID NO:
68, and a HCVR CDR3 sequence of SEQ ID NO:
70;
and,
(5b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
74, a LCVR CDR2 sequence of SEQ ID NO:
76, and a LCVR CDR3 sequence of SEQ ID NO:
78;
or
(6a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
82, a HCVR CDR2 sequence of SEQ ID NO:
84, and a HCVR CDR3 sequence of SEQ ID NO:
86;
and,
(6b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
90, a LCVR CDR2 sequence of SEQ ID NO:
92, and a LCVR CDR3 sequence of SEQ ID NO:
94;
or
(7a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
98, a HCVR CDR2 sequence of SEQ ID NO:
100, and a HCVR CDR3 sequence of SEQ ID NO:
102;
and,
(7b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
106, a LCVR CDR2 sequence of SEQ ID NO:
108, and a LCVR CDR3 sequence of SEQ ID NO:
110;
or
(8a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
114, a HCVR CDR2 sequence of SEQ ID NO:
116, and a HCVR CDR3 sequence of SEQ ID NO:
118;
and,
(8b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
122, a LCVR CDR2 sequence of SEQ ID NO:
124, and a LCVR CDR3 sequence of SEQ ID NO:
128.

76 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/789,961Filed 6 Jan 2021
Priority: 7 Jan 2020
Published: 23 Feb 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61P 35/00
Antineoplastic agents
C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

Application62/957,910Us provisional application · filed 7 Jan 2020
US 12,649,794 B2Related patent
US 2023/0054718 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

(1a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
2, a HCVR CDR2 sequence of SEQ ID NO:
4, and a HCVR CDR3 sequence of SEQ ID NO:
6;
and,
(1b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
10, a LCVR CDR2 sequence of SEQ ID NO:
12, and a LCVR CDR3 sequence of SEQ ID NO:
14;
or
(2a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
18, a HCVR CDR2 sequence of SEQ ID NO:
20, and a HCVR CDR3 sequence of SEQ ID NO:
22;
and,
(2b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
26, a LCVR CDR2 sequence of SEQ ID NO:
28, and a LCVR CDR3 sequence of SEQ ID NO:
30;
or
(3a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
34, a HCVR CDR2 sequence of SEQ ID NO:
36, and a HCVR CDR3 sequence of SEQ ID NO:
38;
and,
(3b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
42, a LCVR CDR2 sequence of SEQ ID NO:
44, and a LCVR CDR3 sequence of SEQ ID NO:
46;
or
(4a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
50, a HCVR CDR2 sequence of SEQ ID NO:
52, and a HCVR CDR3 sequence of SEQ ID NO:
54;
and,
(4b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
58, a LCVR CDR2 sequence of SEQ ID NO:
60, and a LCVR CDR3 sequence of SEQ ID NO:
62;
or
(5a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
66, a HCVR CDR2 sequence of SEQ ID NO:
68, and a HCVR CDR3 sequence of SEQ ID NO:
70;
and,
(5b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
74, a LCVR CDR2 sequence of SEQ ID NO:
76, and a LCVR CDR3 sequence of SEQ ID NO:
78;
or
(6a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
82, a HCVR CDR2 sequence of SEQ ID NO:
84, and a HCVR CDR3 sequence of SEQ ID NO:
86;
and,
(6b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
90, a LCVR CDR2 sequence of SEQ ID NO:
92, and a LCVR CDR3 sequence of SEQ ID NO:
94;
or
(7a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
98, a HCVR CDR2 sequence of SEQ ID NO:
100, and a HCVR CDR3 sequence of SEQ ID NO:
102;
and,
(7b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
106, a LCVR CDR2 sequence of SEQ ID NO:
108, and a LCVR CDR3 sequence of SEQ ID NO:
110;
or
(8a) a heavy chain variable region (HCVR), comprising a HCVR CDR1 sequence of SEQ ID NO:
114, a HCVR CDR2 sequence of SEQ ID NO:
116, and a HCVR CDR3 sequence of SEQ ID NO:
118;
and,
(8b) a light chain variable region (LCVR), comprising a LCVR CDR1 sequence of SEQ ID NO:
122, a LCVR CDR2 sequence of SEQ ID NO:
124, and a LCVR CDR3 sequence of SEQ ID NO:
128.

76 more elements

Facts

Application

17/789,961Filed 6 Jan 2021

Priority

7 Jan 2020

Published

23 Feb 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61P 35/00
Antineoplastic agents
C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies